![](https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1743321630/image_1743321630.jpg?io=getty-c-w1536)
Neurocrine's Pipeline, Including Crinecerfont's Priority Review, Drives Long-Term Growth
Nadzeya Haroshka/iStock via Getty Images Thesis Neurocrine Biosciences, Inc. (NASDAQ:NBIX) has recently announced the FDA accepted the two new drug applications (NDA) associated with Crinecerfont with a priority review, setting PDUFA dates for late …